Type two diabetes mellitus and microvascular complications in patients with coronary artery disease: prevalence, prognosis and choice of antithrombotic therapy
https://doi.org/10.21886/2712-8156-2022-3-4-7-24
Abstract
The review presents the prevalence of both type 2 diabetes mellitus (type 2 DM) and its microvascular complications among patients with coronary heart disease (CHD), and CHD among patients with carbohydrate metabolism disorders. It is shown, that the prognosis of patients with CHD and type 2 DM, especially in the presence of microvascular complications, is extremely unfavorable, and is characterized by a significant increase in the risk of cardiovascular death, myocardial infarction, stroke, terminal stage of the chronic kidney disease and visual impairment. It was noted, that despite the successes achieved in the treatment of CHD, type 2 DM and its microvascular complications, there is a high risk of total, cardiovascular mortality and hospitalizations associated with cardiovascular diseases. In type 2 DM, especially in the presence of microvascular complications and comorbid pathology, special pathogenetic mechanisms of thrombotic risk and bleeding have been identified. Based on large randomized clinical trials, the review evaluated the efficacy and safety of various antithrombotic strategies in patients with stable СРВ, type 2 DM in the presence of microvascular complications and comorbid pathology.
About the Authors
N. A. Koziolova
E.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Natalya A. Koziolova, Dr. Sci. (Med.), professor, head of the Department of Propaedeutic of Internal Diseases №2
Perm
E. A. Polyanskaya
E.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Elena A. Polyanskaya, assistant professor of the Department of Propaedeutic of Internal Diseases №2
Perm
S. V. Mironova
E.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Elena A. Polyanskaya, assistant professor of the Department of Propaedeutic of Internal Diseases №2
Perm
References
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843
2. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25-32. doi: 10.1177/2047487319878371
3. An L, Wang Y, Cao C, Chen T, Zhang Y, Chen L, et al. Screening cardiovascular risk factors of diabetes patients in the primary diabetes clinics. Medicine (Baltimore). 2021;100(30):e26722. doi: 10.1097/MD.0000000000026722
4. Scheen A, Standl E, Tuomilehto J, Zannad F. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J. 2019;40(34):2907-19. doi: 10.1093/eurheartj/ehy677
5. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34(31):2444-52. doi: 10.1093/eurheartj/eht142
6. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22. doi: 10.1016/S0140-6736(10)60484-9
7. Ballotari P, Ranieri SC, Luberto F, Caroli S, Greci M, Giorgi Rossi P, et al. Sex differences in cardiovascular mortality in diabetics and nondiabetic subjects: a population-based study (Italy). Int J Endocrinol. 2015;2015:914057. doi: 10.1155/2015/914057
8. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0
9. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6
10. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 2019;26(2_suppl):7-14. doi: 10.1177/2047487319881021
11. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3-16. doi: 10.1007/s00125-018-4711-2
12. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002;40(5):946-53. doi: 10.1016/s0735-1097(02)02065-x
13. Liu MM, Peng J, Guo YL, Wu NQ, Zhu CG, Gao Y, et al. Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;28(16):1807-16. doi: 10.1093/eurjpc/zwab042
14. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459-502. doi: 10.1161/CIRCULATIONAHA.116.022194
15. The Emerging Risk Factors Collaboration. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52–60. doi: 10.1001/jama.2015.7008
16. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36. doi: 10.1016/S0140-6736(06)68967-8
17. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, et al. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. 2017;40(12):1763-1770. doi: 10.2337/dc17-1091
18. Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-37. doi: 10.1161/CIRCULATIONAHA.118.037885
19. Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care. 2022;45(1):204-12. doi: 10.2337/dc20-2806
20. Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Vision Loss Expert Group of the Global Burden of Disease Study. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016;39(9):1643-9. doi: 10.2337/dc15-2171. Erratum in: Diabetes Care. 2016;39(11):2096.
21. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64. doi: 10.2337/dc11-1909
22. Oshitari T. Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy. Int J Environ Res Public Health. 2021;19(1):439. doi: 10.3390/ijerph19010439
23. Yokomichi H, Nagai A, Hirata M, Mochizuki M, Kojima R, Yamagata Z, et al. Cause-specific mortality rates in patients with diabetes according to comorbid macroand microvascular complications: BioBank Japan Cohort. Endocrinol Diabetes Metab. 2020;4(1):e00181. doi: 10.1002/edm2.181
24. Wang Q, Zhang Z, Chai Q, Shan Y, Lu D, Chen Y, et al. Correlation Between Retinopathy and Coronary Microcirculation Dysfunction in Patients with Type 2 Diabetes Mellitus. Eur J Ophthalmol. 2022:11206721221074201. doi: 10.1177/11206721221074201
25. Fisher VL, Tahrani AA. Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes Metab Syndr Obes. 2017;10:419-34. doi: 10.2147/DMSO.S129797
26. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27(8):1954-61. doi: 10.2337/diacare.27.8.1954. Erratum in: Diabetes Care. 2005;28(2):504.
27. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387-97. doi: 10.1161/CIRCULATIONAHA.106.634949
28. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care. 2001;24(2):339-43. doi: 10.2337/diacare.24.2.339
29. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5(1):17-39. doi: 10.4239/wjd.v5.i1.17
30. Rossing P, Persson F, Frimodt-Møller M. Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. Nephrol Ther. 2018;14 Suppl 1:S31-S37. doi: 10.1016/j.nephro.2018.02.007
31. Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, Górriz JL, Martínez-Castelao A, Navarro-González JF. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014;592(18):3997-4012. doi: 10.1113/jphysiol.2014.272328.
32. Сахарный диабет 2 типа у взрослых. Клинические рекомендации, 2021. Сахарный диабет. 2020;23(2S):4-102. doi: 10.14341/DM20202S
33. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12-154. doi: 10.1053/j.ajkd.2006.12.005
34. Selby NM, Taal M. W. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity and Metabolism. 2020;22(Suppl. 1):3–15. doi: 10.1111/dom.14007
35. Bermejo S, Pascual J, Soler M. J. The large spectrum of renal disease in diabetic patients. Clinical Kidney Journal. 2017;10:255–6. doi: 10.1093/ckj/sfw137
36. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. Journal of the Medical Association of Thailand. 2010;93(Suppl. 6):S228–S241. PMID: 21280541
37. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-32. doi: 10.1046/j.1523-1755.2003.00712.x
38. Ling W, Huang Y, Huang YM, Fan RR, Sui Y, Zhao HL. Global trend of diabetes mortality attributed to vascular complications, 2000-2016. Cardiovasc Diabetol. 2020;19(1):182. doi: 10.1186/s12933-020-01159-5
39. Lemesle G, Meurice T, Tricot O, Lamblin N, Bauters C. Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. J Am Heart Assoc. 2018;7(10):e008354. doi: 10.1161/JAHA.117.008354
40. Guillen-Aguinaga S, Forga L, Brugos-Larumbe A, Guillen-Grima F, Guillen-Aguinaga L, Aguinaga-Ontoso I. Variability in the Control of Type 2 Diabetes in Primary Care and Its Association with Hospital Admissions for Vascular Events. The APNA Study. J Clin Med. 2021;10(24):5854. doi: 10.3390/jcm10245854
41. Gómez-Huelgas R, Sanz-Cánovas J, Cobos-Palacios L, López-Sampalo A, Pérez-Belmonte LM. Glucagonlike peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. Eur J Intern Med. 2022;96:26-33. doi: 10.1016/j.ejim.2021.11.008
42. Carson AP, Tanner RM, Yun H, Glasser SP, Woolley JM, Thacker EL, et al. Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. Ann Epidemiol. 2014;24(8):581-7. doi: 10.1016/j.annepidem.2014.05.007
43. Tomlinson B, Patil NG, Fok M, Lam CWK. Managing dyslipidemia in patients with Type 2 diabetes. Expert Opin Pharmacother. 2021;22(16):2221-34. doi: 10.1080/14656566.2021.1912734
44. Strauss MH, Hall AS. The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus. Can J Diabetes. 2018;42(2):124-9. doi: 10.1016/j.jcjd.2017.09.011
45. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407-18. doi: 10.1056/NEJMoa1608664
46. Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, et al. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J. 2021;42(23):2235-59. doi: 10.1093/eurheartj/ehab128
47. Kisioglu SV, Habiboglu I, Gunay YE, Durak S, Karakullukcu S, Fidan S. Gastrointestinal Bleeding Risk Factors in Patients with Type 2 Diabetes Mellitus. J Coll Physicians Surg Pak. 2022;32(1):15-9. doi: 10.29271/jcpsp.2022.01.15
48. Lin HY, Niu SW, Kuo IC, Lim LM, Hwang DY, Lee JJ, et al. Hematuria and Renal Outcomes in Patients With Diabetic Chronic KidneyDisease. Am J Med Sci. 2018;356(3):268-76. doi: 10.1016/j.amjms.2018.06.005
49. Okada S, Samejima KI, Matsui M, Morimoto K, Furuyama R, Tanabe K, et al. Microscopic hematuria is a risk factor for end-stage kidney disease in patients with biopsyproven diabetic nephropathy. BMJ Open Diabetes Res Care. doi: 10.1136/bmjdrc-2020-001863
50. Zhang J, Wang Y, Li L, Zhang R, Guo R, Li H, et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephronpathy. Ren Fail. 2018;40(1):243-51. doi: 10.1080/0886022X.2018.1456453
51. Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, et al. REACH Registry Investigators. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019;73(25):3281-91. doi: 10.1016/j.jacc.2019.04.046
52. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020;41(45):4317.
53. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi: 10.15829/1560-4071-2020-4076
54. Козиолова Н.А., Караваев П.Г., Веклич А.С. Выбор антитромботической терапии у больных ишемической болезнью сердца и сахарным диабетом 2-го типа. Кардиология. 2020;60(4):109-119. doi: 10.18087/cardio.2020.4.n1042
55. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance. Am J Cardiol. 2009;103(10):1359-63. doi: 10.1016/j.amjcard.2009.01.342
56. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. doi: 10.1056/NEJMoa1409312
57. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015;131(12):1047-53. doi: 10.1161/CIRCULATIONAHA.114.013774
58. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732-2740. doi: 10.1016/j.jacc.2016.03.529
59. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebocontrolled trial. Lancet. 2018;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Erratum in: Lancet. 2017: PMID: 29132879
60. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-1320. doi: 10.1056/NEJMoa1908077
61. Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200-6. doi: 10.1093/ehjcvp/pvz020
62. Leiter LA, Bhatt DL, McGuire DK, Teoh H, Fox K, Simon T, et al. THEMIS Steering Committee and Investigators. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol. 2021;77(19):2366-77. doi: 10.1016/j.jacc.2021.03.298
63. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020;141(23):1841-54. doi: 10.1161/CIRCULATIONAHA.120.046448
64. El-Andari R, Bozso SJ, Fialka NM, Kang JJ, Nagendran J, Nagendran J. Coronary Revascularization for Patients with Diabetes Mellitus: A Contemporary Systematic Review and Meta-Analysis. Ann Surg. 2022. doi: 10.1097/SLA.0000000000005391
65. Writing Committee Members, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):197-215. doi: 10.1016/j.jacc.2021.09.005
66. Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, et al. COMPASS Investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASSPCI). Circulation. 2020;141(14):1141-51. doi: 10.1161/CIRCULATIONAHA.119.044598. Erratum in: Circulation. 2020;141(23):e905.
67. Sellke FW. Secondary prevention after coronary artery bypass grafting: Anticoagulation and antiplatelet therapy is only one factor. J Card Surg. 2021;36(3):1100-2. doi: 10.1111/jocs.15286
68. van Diepen S, Fuster V, Verma S, Hamza TH, Siami FS, Goodman SG, et al. Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. J Am Coll Cardiol. 2017;69(2):119-27. doi: 10.1016/j.jacc.2016.10.043
69. Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASSCABG Study. J Am Coll Cardiol. 2019;73(2):121-30. doi: 10.1016/j.jacc.2018.10.048
70. Alexander JH. Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft. J Am Coll Cardiol. 2019;73(2):131-3. doi: 10.1016/j.jacc.2018.10.049
71. Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, et al. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol. 2020;19(1):179. doi: 10.1186/s12933-020-01153-x
72. De Luca L, Formigli D, Meessen J, Uguccioni M, Cosentino N, Paolillo C, et al. START Investigators. COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. Eur Heart J Qual Care Clin Outcomes. 2021;7(5):513-20. doi: 10.1093/ehjqcco/qcaa054
73. Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019;73(18):2243-50. doi: 10.1016/j.jacc.2019.02.048
74. Rashid M, Kwok CS, Gale CP, Doherty P, Olier I, Sperrin M, et al. Impact of co-morbid burden on mortality in patients with coronary heart disease, heart failure, and cerebrovascular accident: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2017;3(1):20-36. doi: 10.1093/ehjqcco/qcw025
75. Zhou D, Wang L, Ding S, Shen M, Qiu H. Phenotypic Disease Network Analysis to Identify Comorbidity Patterns in Hospitalized Patients with Ischemic Heart Disease Using Large-Scale Administrative Data. Healthcare (Basel). 2022;10(1):80. doi: 10.3390/healthcare10010080
76. Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021;78(1):14-23. doi: 10.1016/j.jacc.2021.04.083
77. İnci H. Evaluation of multiple drug use in patients with type 2 diabetes mellitus. Diabetol Int. 2021;12(4):399-404. doi: 10.1007/s13340-021-00495-5
78. Al-Musawe L, Torre C, Guerreiro JP, Rodrigues AT, Raposo JF, Mota-Filipe H, Martins AP. Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetesattending specialty care institution. Eur J Clin Pharmacol. 2021;77(9):1397-407. doi: 10.1007/s00228-021-03107-y
79. Cook HE, Hewitt JH, Patterson EP, Randolph AE. Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants. J Pharm Pract. 2022:8971900211059411. doi: 10.1177/08971900211059411
80. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, et al. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2021:pvab050. doi: 10.1093/ehjcvp/pvab050
81. Zhu H, Xu X, Fang X, Ying F, Song L, Gao B, et al. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Metaanalysis of Randomized Controlled Trials. J Am Heart Assoc. 2021;10(6):e019184. doi: 10.1161/JAHA.120.019184
Review
For citations:
Koziolova N.A., Polyanskaya E.A., Mironova S.V. Type two diabetes mellitus and microvascular complications in patients with coronary artery disease: prevalence, prognosis and choice of antithrombotic therapy. South Russian Journal of Therapeutic Practice. 2022;3(4):7-24. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-4-7-24
Views:
1928
Email this article 